Stem cell therapies for pulmonary fibrosis: emerging hope through ongoing challenges
Shi H., Geng R., Liu H.
Clinical Trial, published in Stem Cell Res Ther (2026) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Clinical Trial
- Journal
- Stem Cell Res Ther (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41588478
- PMCID
- PMC12836833
- DOI
- 10.1186/s13287-025-04765-w
Abstract (original English)
Stem cell therapy represents an emerging intervention for pulmonary fibrosis (PF), a severe lung disease lacking effective treatments. We conducted a systematic retrospective review of stem cell clinical trials for PF registered up to the end of 2024, utilizing the Trialtrove database alongside other registries.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.